Myastad (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myastad, is a immunosuppressant (IMP dehydrogenase inhibitor) presented as an oral formulation for oral use. It is used to prevent organ transplant rejection and to treat lupus nephritis and other autoimmune diseases in adult patients.

GNH USA supplies Myastad as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myastad is an immunosuppressant used in conditions where suppression of the immune response is required. - Organ transplant rejection: helps prevent graft rejection by inhibiting lymphocyte proliferation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Other autoimmune diseases: controls disease activity in conditions such as rheumatoid arthritis or vasculitis.

Myastad may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial pain. Serious or Rare Side Effects: - Bone marrow suppression: anemia, leukopenia, thrombocytopenia. - Severe infections: opportunistic or systemic infections. - Renal dysfunction: worsening kidney function.

When using Myastad, several precautions should be observed. - Dose adjustment in renal impairment: reduce dose based on creatinine clearance. - Monitor blood counts regularly: watch for leukopenia, anemia, thrombocytopenia. - Assess liver function: periodic LFT testing recommended. - Avoid use in pregnancy: category D, risk to fetus. - Contraception required for women of childbearing potential. - Store at room temperature: keep in original container, protect from moisture and light.

Myastad can interact with other medicines, requiring careful management. Major Interactions (Avoid): - Live vaccines: may cause severe infection. - Azathioprine: additive bone marrow suppression. - Antacids containing aluminum or magnesium: reduce absorption. Moderate Interactions (Monitor Closely): - Rifampin: may decrease mycophenolic acid levels. - Cyclosporine or tacrolimus: may increase exposure, monitor levels. - Warfarin: potential alteration of INR, monitor coagulation.